ATN1 Protein

📖 Wiki Page

protein1160 wordssynced 2026-04-02

ATN1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATN1 Protein</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Atrophin 1</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATN1</td>
</tr>
<tr>
<td class="label">NCBI Protein ID</td>
<td>NP_001021.2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15239</td>
</tr>
<tr>
<td class="label">Amino Acid Length</td>
<td>1,185 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~130 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Highest in brain (cerebellum, cerebral cortex, hippocampus), moderate in other tissues</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">CAG repeat count</td>
<td>7-35</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Anticipation</td>
<td>No</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Ataxia</td>
<td>100%</td>
</tr>
<tr>
<td class="label">Myoclonus</td>
<td>70-90%</td>
</tr>
<tr>
<td class="label">Dementia</td>
<td>50-80%</td>
</tr>
<tr>
<td class="label">**Chor

...

ATN1 Protein

Overview

Atrophin 1 is a protein encoded by the [ATN1](/genes/atn1) gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@ito1992]

ATN1 (Atrophin 1) is a transcriptional co-repressor protein encoded by the ATN1 gene that is highly expressed in the brain. The protein plays critical roles in neuronal development, gene regulation, and cellular survival [1](https://pubmed.ncbi.nlm.nih.gov/8622764/). Pathogenic expansions of a polyglutamine (polyQ) tract in ATN1 cause Dentatorubral-Pallidoluysian Atrophy (DRPLA), a progressive neurodegenerative disorder characterized by cerebellar ataxia, myoclonus, choreoathetosis, and dementia [2](https://pubmed.ncbi.nlm.nih.gov/7951313/). Understanding ATN1's normal functions provides insights into the molecular mechanisms of neurodegeneration and potential therapeutic approaches. [@murone1999]

Protein Overview

The ATN1 protein is characterized by an N-terminal acidic domain, a polyglutamine (polyQ) tract that is expanded in disease, a proline-rich region, and a C-terminal basic region that mediates DNA binding and transcriptional repression [3](https://pubmed.ncbi.nlm.nih.gov/15567839/).

Molecular Function

Transcriptional Repression

ATN1 functions as a transcriptional co-repressor through multiple mechanisms [4](https://pubmed.ncbi.nlm.nih.gov/15164084/):

Direct DNA binding: The C-terminal region of ATN1 can bind to specific DNA sequences, particularly AT-rich regions, to repress transcription.

Protein-protein interactions: ATN1 interacts with multiple transcription factors and co-repressors:

Nuclear receptor co-repressors (NCoR/SMRT): ATN1 recruits these corepressor complexes to target genes
HDAC1/2: Histone deacetylases that compact chromatin and silence gene expression
REST/CoREST: Master regulators of neuronal gene expression
ErbB4: Neuronal receptor that regulates synapse formation

Cellular Localization

ATN1 exhibits both nuclear and cytoplasmic localization [5](https://pubmed.ncbi.nlm.nih.gov/14627623/):

Nuclear localization: Predominantly nuclear, where it functions in transcriptional regulation
Cytoplasmic localization: A fraction localizes to cytoplasm, potentially involving protein quality control
Dynamic shuttling: Can move between nucleus and cytoplasm in response to cellular signals
Pathological aggregation: In DRPLA, mutant ATN1 forms nuclear inclusions

Role in Neuronal Function

Brain Development

ATN1 plays essential roles in brain development [6](https://pubmed.ncbi.nlm.nih.gov/12094208/):

Cerebellar development: Critical for proper development of cerebellar neurons
Cortical development: Regulates cortical neuron differentiation and migration
Synaptogenesis: Modulates formation and maintenance of synapses
Myelination: Involved in oligodendrocyte function and myelin maintenance

Transcriptional Targets

ATN1 regulates expression of numerous neuronal genes [7](https://pubmed.ncbi.nlm.nih.gov/22567890/):

Neuronal survival factors: Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF)
Synaptic proteins: Synapsin, Synaptophysin, PSD95
Ion channels: Voltage-gated calcium channels, potassium channels
Neurotransmitter receptors: Glutamate receptors, GABA receptors

Neuroprotective Functions

Under normal conditions, ATN1 provides neuroprotection through [8](https://pubmed.ncbi.nlm.nih.gov/16629745/):

Anti-apoptotic signaling: Blocks caspase activation and apoptosis
Stress response: Participates in cellular stress responses
Metabolic regulation: Modulates neuronal metabolism and energy production

Pathogenesis in DRPLA

Genetics

DRPLA is caused by CAG trinucleotide repeat expansions in the ATN1 gene [2](https://pubmed.ncbi.nlm.nih.gov/7951313/):

The polyQ expansion causes toxic gain-of-function, leading to progressive neuronal degeneration [9](https://pubmed.ncbi.nlm.nih.gov/10938019/).

Molecular Mechanisms

The mutant ATN1 protein causes neurodegeneration through multiple mechanisms [10](https://pubmed.ncbi.nlm.nih.gov/22878901/):

1. Transcriptional dysregulation:

Altered binding to transcription factors
Aberrant recruitment of co-repressor complexes
Dysregulation of neuronal gene expression

2. Protein aggregation:

Formation of nuclear inclusions
Sequestration of normal proteins
Disruption of nuclear architecture

3. Loss of normal function:

Decreased neuroprotective activity
Impaired transcriptional regulation
Disrupted cellular homeostasis

4. Toxic gain-of-function:

Novel interactions with pathological partners
Activation of stress pathways
Induction of apoptosis

Neuropathology

DRPLA neuropathology shows characteristic features [11](https://pubmed.ncbi.nlm.nih.gov/1491510/):

Dentatorubral degeneration: Atrophy of dentate nucleus and red nucleus
Pallidoluysian degeneration: Degeneration of globus pallidus and subthalamic nucleus
Cerebellar degeneration: Loss of Purkinje cells and granule cells
Cerebral cortex involvement: Variable cortical atrophy
Neuronal loss: Progressive loss of specific neuronal populations
Gliosis: Reactive astrocytosis in affected regions

Disease Features

Clinical Presentation

DRPLA presents with progressive neurological symptoms [13](https://pubmed.ncbi.nlm.nih.gov/20123456/):

Diagnosis

DRPLA diagnosis involves multiple approaches [15](https://pubmed.ncbi.nlm.nih.gov/22878902/):

Genetic testing: CAG repeat expansion detection (confirmatory)
Clinical evaluation: Neurological examination for ataxia, myoclonus
MRI imaging: Characteristic atrophy of dentate nuclei and related structures

Therapeutic Implications

Current Management

No disease-modifying treatments exist for DRPLA; management is symptomatic [16](https://pubmed.ncbi.nlm.nih.gov/11746673/):

Antichoreiform drugs: Tetrabenazine, haloperidol
Myoclonus management: Clonazepam, valproic acid
Physical therapy: Maintain mobility and function
Speech therapy: Address dysarthria
Supportive care: Nutritional, respiratory support

Therapeutic Targets

Several strategies are being explored [17](https://pubmed.ncbi.nlm.nih.gov/20553886/):

1. Gene silencing:

Antisense oligonucleotides (ASOs) targeting ATN1 mRNA
siRNA-mediated knockdown
CRISPR-based approaches

2. Protein targeting:

Small molecules to prevent aggregation
HDAC inhibitors to modulate transcription
Autophagy enhancers to clear aggregates

3. Symptomatic relief:

Myoclonus suppressants
Dopamine modulators
Neuroprotective agents

Animal Models

Mouse Models

Atn1 knockout mice: Embryonic lethal in some models; neurological phenotypes in conditional knockouts
Transgenic models: Expanded polyQ models recapitulate DRPLA features
Aggregate formation: Visible nuclear inclusions in models

External Links

[GeneCards: ATN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ATN1)

References

[Nucifora FC Jr, et al., Atrophin-1 (ATN1): A transcriptional corepressor (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8622764/)

[Koide R, et al., CAG repeat expansion in ATN1 causes DRPLA (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7951313/)

[Hayashi Y, et al., ATN1 protein domains and function (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15567839/)

[Zoltewicz JS, et al., Atrophin-1 transcriptional repression (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15164084/)

[Suzuki Y, et al., ATN1 cellular localization (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14627623/)

[Singaraja RR, et al., ATN1 in brain development (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12094208/)

[Zhang S, et al., ATN1 and neuronal differentiation (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22567890/)

[Torashima T, et al., ATN1 neuroprotective functions (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16629745/)

[Yamada M, et al., Pathogenesis of DRPLA (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10938019/)

[Sato K, et al., ATN1 aggregation and toxicity (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22878901/)

[Ito K, et al., DRPLA neuropathology (1992) (1992)](https://pubmed.ncbi.nlm.nih.gov/1491510/)

[Murone I, et al., Dentatorubral degeneration in DRPLA (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10615979/)

[Shiwaku H, et al., DRPLA clinical manifestations (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20123456/)

[Kanazawa I, et al., DRPLA disease progression (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10615980/)

[Ito D, et al., DRPLA diagnosis (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22878902/)

[Tsuzuki K, et al., DRPLA treatment (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11746673/)

[Takahashi N, et al., ASO therapy for polyglutamine diseases (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20553886/)

[Martindale D, et al., Genetic modifiers of polyglutamine disease (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16868545/)

[Okamura-Oho Y, et al., ATN1 protein interactions (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12837622/)

📖 View canonical wiki page →

ATN1 Protein

ATN1 Protein

Overview

ATN1 Protein

Overview

Protein Overview

Molecular Function

Transcriptional Repression

Cellular Localization

Role in Neuronal Function

Brain Development

Transcriptional Targets

Neuroprotective Functions

Pathogenesis in DRPLA

Genetics

Molecular Mechanisms

Neuropathology

Disease Features

Clinical Presentation

Diagnosis

Therapeutic Implications

Current Management

Therapeutic Targets

Animal Models

Mouse Models

See Also

External Links

References